Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001193125-26-102252
Filing Date
2026-03-11
Accepted
2026-03-11 16:28:55
Documents
75
Period of Report
2025-12-31

Document Format Files

Seq Description Document Type Size
1 10-K tnya-20251231.htm   iXBRL 10-K 3110723
2 EX-4.2 tnya-ex4_2.htm EX-4.2 34528
3 EX-10.11 tnya-ex10_11.htm EX-10.11 57982
4 EX-23.1 tnya-ex23_1.htm EX-23.1 4380
5 EX-31.1 tnya-ex31_1.htm EX-31.1 20940
6 EX-32.1 tnya-ex32_1.htm EX-32.1 14409
7 GRAPHIC img157606814_0.jpg GRAPHIC 186539
  Complete submission text file 0001193125-26-102252.txt   11888427

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT tnya-20251231.xsd EX-101.SCH 1650545
78 EXTRACTED XBRL INSTANCE DOCUMENT tnya-20251231_htm.xml XML 1825143
Mailing Address 171 OYSTER POINT BLVD., SUITE 500 SOUTH SAN FRANCISCO CA 94080
Business Address 171 OYSTER POINT BLVD., SUITE 500 SOUTH SAN FRANCISCO CA 94080 415-865-2066
Tenaya Therapeutics, Inc. (Filer) CIK: 0001858848 (see all company filings)

EIN.: 813789973 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-40656 | Film No.: 26743782
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)